Advanced Search

    column
    Treatment of HER2 Mutant Non-Small Cell Lung Cancer: The Next Breakthrough
    YU Ying, FAN Yun
    2022, 22(4): 193-197. DOI: 10.12019/j.issn.1671-5144.2022.04.001
    Abstract FullText HTML PDF
    Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations
    LIU Xin-yu, REN Sheng-xiang, SUN Yue-li
    2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002
    Abstract FullText HTML PDF
    The Dawn Is Dawing, the Future Is Promising: Efficacy and Safety of pan-HER Inhibitors in Advanced Lung Adenocarcinoma With HER2 Mutations
    YANG Guang-jian, WANG Yan, KE E-e
    2022, 22(4): 202-206. DOI: 10.12019/j.issn.1671-5144.2022.04.003
    Abstract FullText HTML PDF
    From Bench to Bedside, the Development Path of HER2 Antibody-Drug Conjugate
    XU Chong-rui, YIN Kai
    2022, 22(4): 207-211. DOI: 10.12019/j.issn.1671-5144.2022.04.004
    Abstract FullText HTML PDF
    The Application Value of cfDNA Detection Combined With Liver MRI in the Screening of Hepatocellular Carcinoma
    XU Juan, XIN Jie-jing, LI Yi, LV Qi-jun, FENG Xue, HUANG Hai-yan
    2022, 22(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2022.04.005
    Abstract FullText HTML PDF
    Application of Setup Method Based on Planned Bed Value in Intensity-Modulated Radiation Therapy After Breast-Conserving Surgery
    HUANG Dian-yi, LIU Ping-ping, FANG Liang-yi, LONG Liang, LV Feng-quan, CEN Wei-jian, ZENG Zi-jun
    2022, 22(4): 217-223. DOI: 10.12019/j.issn.1671-5144.2022.04.006
    Abstract FullText HTML PDF
    Effect on the Accuracy by Colposcopy Among Different Cervical Conversion Area Types for the Patients of Cervical Intraepithelial Neoplasia
    LI Er-lei, AN Guo-qian, DENG Hong-wen, LIU Dong-mei
    2022, 22(4): 224-229. DOI: 10.12019/j.issn.1671-5144.2022.04.007
    Abstract FullText HTML PDF
    Construction and Validation of Endometriosis Associated Ovarian Cancer Risk Model
    YAN Na, ZOU Li-sha, TANG Jie, ZHANG Ling-li
    2022, 22(4): 230-236. DOI: 10.12019/j.issn.1671-5144.2022.04.008
    Abstract FullText HTML PDF
    Efficacy and Safety of Camrelizumab Combined With Anlotinib in the Treatment of Intermediate-Advanced Liver Cancer
    CAI Yu, ZHAO Chang-hai, LUO Li-qiong
    2022, 22(4): 237-242. DOI: 10.12019/j.issn.1671-5144.2022.04.009
    Abstract FullText HTML PDF
    Characteristics of Bispecific Antibodies and Their Clinical Application in Therapy of Lung Cancer
    LIU Si-yang Maggie, ZHOU Qing, LI Yang-qiu, WU Yi-long
    2022, 22(4): 243-253. DOI: 10.12019/j.issn.1671-5144.2022.04.010
    Abstract FullText HTML PDF
    Option of Local Treatment in Huge Lung Tumor After Systematic Treatment
    SUN Yue-li, TU Hai-yan
    2022, 22(4): 254-256. DOI: 10.12019/j.issn.1671-5144.2022.04.011
    Abstract FullText HTML PDF